AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

VCEL · NASDAQ · Biotechnology

Vericel (VCEL)

Markets patient-specific cell therapies for knee-cartilage repair and severe burns, plus enzymatic burn debridement.

$40.22

After hours0.00 (0.00%)

At close$40.22(+1.69%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	46	65	51	53	58	75	53	63	68	93	68	77
Cost of revenue	15	16	16	16	16	17	16	17	18	20	19	21
Gross profit	31	49	35	37	42	58	36	47	50	73	49	56
	36	36	41	43	44	40	49	49	46	51	57	56
Research & development	6	5	6	7	6	5	7	7	6	7	8	7
Selling, general & administrative	30	31	34	35	38	35	42	42	40	43	49	48
Operating income	−5	13	−5	−6	−2	18	−13	−2	3	22	−8	0
	1	1	2	1	2	1	2	1	2	2	2	2
Interest income	1	1	2	2	2	2	2	2	2	2	2	2
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−1	−2	−2	−2	−2	−2	−2	−2	−2	−2	−2	−2
Income before tax	−4	14	−4	−5	−1	20	−11	−1	5	24	−6	2
Income tax expense	0	1	0	0	0	0	0	0	0	1	0	0
Net income from continuing operations	−4	13	−4	−5	−1	20	−11	−1	5	23	−6	2
Net income	−4	13	−4	−5	−1	20	−11	−1	5	23	−6	2
EPS, basic	−$0.08	$0.27	−$0.08	−$0.10	−$0.02	$0.40	−$0.23	−$0.01	$0.10	$0.46	−$0.12	$0.04
EPS, diluted	−$0.08	$0.26	−$0.08	−$0.10	−$0.02	$0.38	−$0.23	−$0.01	$0.10	$0.45	−$0.12	$0.04
Weighted average shares, basic	48	48	48	49	49	49	50	50	50	51	51	51
Weighted average shares, diluted	48	51	48	49	49	52	50	50	52	52	51	51
EBITDA	−3	15	−2	−3	1	22	−8	2	8	28	−3	6
Depreciation & amortization	1	1	1	1	1	1	3	3	3	3	3	3
EBIT	−4	14	−4	−5	−1	20	−11	0	5	24	−6	2